Illumina, Inc.

ILMN
Precision medicineHealthcare diagnosticsGenomic analysis
$216.24vs prev close-3.16(-1.44%)
$88.0052W Range$220.43
97% from low
+21.68 (+11.17%)Past 1M
Price
ARK Trade PatternPREMIUM
1M Trades
3 sells
Concentrated sells
1M net buy
-$9.9M
-51K shares
Portfolio Weight
1.22%
1M -0.08%p
Holding ETFs
2 ETFs
ARKG · ARKK

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -17.8% · Market value -15.4% · Weight -0.08%p

Trade Intensity
Minor adjustment

Basis: 3 sells · 0 buys in 1M

Trade Log3-day SELL streak
DateActionETFSharesCloseEst. total
26.08.19SELLARKK15,613$205.00$3.2M
26.08.18SELLARKK32,648$188.29$6.1M
26.07.29SELLARKK2,917$194.82$568.3K
26.07.20SELLARKK16,027$184.68$3.0M
26.07.16SELLARKK28,117$190.25$5.3M
26.07.08SELLARKG · ARKK52,418$187.81$9.8M
26.07.07SELLARKG · ARKK40,787$191.76$7.8M
26.07.02SELLARKK21,279$188.68$4.0M
26.06.11SELLARKK46,265$166.21$7.7M
26.03.26SELLARKK14,418$124.40$1.8M
26.03.25SELLARKK31,986$126.20$4.0M
26.02.03SELLARKK6,564$135.43$889.0K
26.02.02SELLARKK4,274$141.13$603.2K
26.01.30SELLARKK22,646$144.81$3.3M
26.01.29SELLARKG · ARKK35,897$149.69$5.4M
08.19SELL
15,613
ARKKClose$205.00Est. total$3.2M
08.18SELL
32,648
ARKKClose$188.29Est. total$6.1M
07.29SELL
2,917
ARKKClose$194.82Est. total$568.3K
07.20SELL
16,027
ARKKClose$184.68Est. total$3.0M
07.16SELL
28,117
ARKKClose$190.25Est. total$5.3M
07.08SELL
52,418
ARKG · ARKKClose$187.81Est. total$9.8M
07.07SELL
40,787
ARKG · ARKKClose$191.76Est. total$7.8M
07.02SELL
21,279
ARKKClose$188.68Est. total$4.0M
06.11SELL
46,265
ARKKClose$166.21Est. total$7.7M
03.26SELL
14,418
ARKKClose$124.40Est. total$1.8M
03.25SELL
31,986
ARKKClose$126.20Est. total$4.0M
02.03SELL
6,564
ARKKClose$135.43Est. total$889.0K
02.02SELL
4,274
ARKKClose$141.13Est. total$603.2K
01.30SELL
22,646
ARKKClose$144.81Est. total$3.3M
01.29SELL
35,897
ARKG · ARKKClose$149.69Est. total$5.4M
1 / 5

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline
Institutional Holders
1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest
LIVE
Shares
752,739
Portfolio Weight
1.22%
in ETF 4.32%
Est. Value
$150M
30D Net
-$28M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Analyst recommendation distribution20
Overall Opinion
Buy
Strong Buy
4
Buy
6
Hold
6
Sell
1
Strong Sell
3
Analyst Targets
avg.
$198.89
vs Current -6.7% downside
Current$213.24
Low ~ High$113.00 ~ $230.00
Firm
Position
Price Target
Upside / Downside
Close Price
Action
Date
Canaccord Genuity
Hold
$205.00
-3.86%
Maintain
2026-08-03
Citigroup
Sell
$113.00
-47.01%
Maintain
2026-08-03
Piper Sandler
Overweight
$225.00
+5.51%
Maintain
2026-08-03
RBC Capital
Outperform
$230.00
+7.86%
Maintain
2026-07-31
JP Morgan
Overweight
$230.00
+7.86%
Maintain
2026-07-31
1 / 4
Avg Target
$198.89
vs Current -6.7% downside
Buy
20 analysts
Strong Buy 4Buy 6Hold 6Sell 1Strong Sell 3
Low $113.00
Current $213.24
High $230.00
FirmPositionTargetUpsideCloseActionDate
Canaccord GenuityHold$205.00-3.86%Maintain26.08.03
CitigroupSell$113.00-47.01%Maintain26.08.03
Piper SandlerOverweight$225.00+5.51%Maintain26.08.03
RBC CapitalOutperform$230.00+7.86%Maintain26.07.31
JP MorganOverweight$230.00+7.86%Maintain26.07.31
1 / 4

Price Information

Previous Close$213.24
Open$212.94
Day Range$208.63 - $220.43
52-Week Range$88.00 - $220.43
1-Year Change120.15%

Trading Volume

Volume1,917,222
Avg Volume (3mo)1,989,254

Valuation

Market Cap33.1B
Book Value$18.80
Shares Outstanding151,000,000

Financials

Revenue (TTM)4.5B
Net Income824.0M
EPS$5.35
EBITDA1.2B

Profitability

P/E Ratio41.01
P/B Ratio11.67
Return on Equity (ROE)32.34%
Return on Assets (ROA)8.67%
Profit Margin18.34%
EV/EBITDA29.86
Beta1.46

Dividend

Dividend Rate-
Dividend Yield-

Technical

RSI(14)66.32
Company Overview

Illumina, Inc. is a global leader in providing advanced sequencing and array-based solutions for genetic and genomic analysis. Their main products include instruments, consumables like reagents and flow cells, and various sequencing kits for whole genomes or targeted regions. Illumina serves a broad market including research centers, academic institutions, hospitals, and pharmaceutical and biotechnology companies.

P/B
11.67
High valuation
ROE
32.3%
High return
Beta
1.46
Market Volatility
RSI(14)
66.3
Neutral zone

AI-generated summary. Not investment advice.

Recent News

Mymoneywood cross-analyzes and curates publicly available SEC 13F-HR filing data. We do not provide investment advice and do not recommend buying or selling any specific securities.

Past performance does not guarantee future results. All investment decisions and responsibilities rest with the user.

Terms of Service·Investment Disclaimer·Privacy Policy·Refund Policy

Always summer | biz@mymoneywood.com
© 2026 Always summer. All rights reserved.

Enter your email below to sign up for the newsletter.

By entering your email you agree to our Privacy Policy. You can unsubscribe anytime.